Transgenex Nanobiotech Inc., a biotechnology spinout from the University of South Florida founded by Drs. Shyam and Subhra Mohapatra, received a $1.49 million Phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute on March 27, 2017. The contract, announced by the Florida Institute for the Commercialization of Public Research, supports further development of Transgenex’s TN-1008 technology, a nanoparticle-delivered inhibitor targeting cancer stem cell pathways. This funding follows the company’s successful Phase I project and aims to advance nano-encapsulated TN-1008 for the treatment of lung and other cancers.